Molecular Genetics of Schizophrenia
- Conditions
- Schizophrenia
- Registration Number
- NCT00006418
- Lead Sponsor
- NorthShore University HealthSystem
- Brief Summary
This study will create a DNA collection with blood samples from families with at least two siblings who have schizophrenia symptoms. This collection will help scientists identify genes that predispose people to schizophrenia.
- Detailed Description
Each site will recruit individuals in a large geographic area, and use efficient ascertainment strategies and assessment procedures in order to maximize the number collected. Subjects thought to have schizophrenia will be assessed by personal and family interviews and a review of medical records. Diagnoses will be made by consensus best-estimate procedures. Blood specimens will be obtained from all individuals with schizophrenia or schizoaffective disorder plus their available parents and also the control individuals. A clinical self-assessment will be administered to each control subject. The assessment will include validated self-assessments of lifetime major depression, anxiety disorders, and substance use, and self-reported history of bipolar or psychotic symptoms. Permanent cell lines will be created and DNA extracted at the NIMH-sponsored Center for Genetic Studies. At the end of the four-year project period, biological materials and blinded pedigree and clinical data will be made available to the scientific community for genetic studies of schizophrenia and related disorders. The control sample will, however, be released in a staggered fashion, twice during each fiscal year, to start during the 2nd year of recruitment. The informed consent for controls includes consent for specimens to be used in research on the genetics of any medical disorder. In years 3 and 4, we will undertake association analyses. Power analyses suggest that this study will have excellent power to detect loci associated with genes with relatively small etiologic effects. Data derived from this study will potentially have applications for the treatment and prevention of schizophrenia.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10800
- Individuals thought to have schizophrenia or schizoaffective disorder, be the parent of such an individual, or be in the matched control group of unrelated individuals not thought to have schizophrenia or schizoaffective disorder
- Unable to give informed consent to all aspects of the study
- Psychotic disorder judged to be secondary to substance use, psychotic disorder that appears to be secondary to a known medical or neurological disorder, or severe mental retardation
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (10)
University of California, Irvine
🇺🇸Irvine, California, United States
Evanston Northwestern Healthcare Research Institute
🇺🇸Evanston, Illinois, United States
Washington University School of Medicine
🇺🇸St. Louis, Missouri, United States
University of Queensland
🇦🇺Brisbane, Queensland, Australia
Emory University
🇺🇸Atlanta, Georgia, United States
University of Iowa College of Medicine
🇺🇸Iowa City, Iowa, United States
Mount Sinai School of Medicine
🇺🇸New York, New York, United States
University of Pennsylvania School of Medicine
🇺🇸Philadelphia, Pennsylvania, United States
University of Colorado Health Sciences Center
🇺🇸Denver, Colorado, United States
Louisiana State University Health Sciences Center
🇺🇸New Orleans, Louisiana, United States